OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations

May 26th 2023

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.

Dr Champ on Boost Radiotherapy in Breast Cancer

May 26th 2023

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

Dr Wang on the Future of Targeted Therapies in AML

May 26th 2023

Eunice Wang, MD, discusses how the continued development of targeted therapies could improve the future treatment paradigm in acute myeloid leukemia.

Dr Park on the Role of Radiation Therapy in NSCLC

May 26th 2023

Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.

Dr Cardin on the Influence of Comorbidities on Treatment Selection in Pancreatic Cancer

May 26th 2023

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

Dr Zonder on the Real-World Use of Ixazomib-based Therapy in R/R Multiple Myeloma

May 26th 2023

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Dr Bal on the Clinical Implications of Cilta-cel in R/R Multiple Myeloma

May 25th 2023

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Chiang on Frontline Treatment Combinations in ES-SCLC

May 25th 2023

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.

Dr Omene on Decreasing Disparities in Breast Cancer

May 25th 2023

Coral O. Omene, MD, PhD, discusses the importance of a multidisciplinary, patient-focused approach to mitigating disparities in the care of patients with breast cancer.

Dr Wise on the Optimal Use of Treatment Intensification in mHSPC

May 25th 2023

David R. Wise, MD, PhD, discusses changes in the optimal use of intensified treatment regimens in patients with metastatic hormone-sensitive prostate cancer.

Dr Cohen on Key Trials Supporting the Use of PARP Inhibitors in Ovarian Cancer

May 25th 2023

Joshua G. Cohen, MD, FACOG, FACS, discusses key trials supporting the use of PARP inhibitor maintenance therapy in upfront setting in ovarian cancer.

Dr Kim on the Investigation of RLY-4008 in FGFR2+ Cholangiocarcinoma

May 25th 2023

Richard Kim, MD, discusses the investigation of RLY-4008 for the treatment of patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Dr Eisfeld on Timing of Molecular Testing and the Start of Treatment in AML

May 25th 2023

Ann-Kathrin Eisfeld, MD, discusses factors to consider when deciding whether to start treatment right away or wait for molecular testing results in patients with acute myeloid leukemia.

Dr Goldberg on Investigational Agents in EGFR-mutant NSCLC

May 24th 2023

Sarah Goldberg, MD, MPH, discusses ongoing investigations with antibody-drug conjugates and bispecific antibodies in patients with non–small cell lung cancer harboring EGFR mutations.

Dr Grivas on Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Cancer

May 24th 2023

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC

May 24th 2023

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

​​Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma

May 24th 2023

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC

May 23rd 2023

Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

May 23rd 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Dr Phillips on the Implications of the FDA Approval of Pirtobrutinib in R/R Mantle Cell Lymphoma

May 23rd 2023

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

NEXT PAGE
PREVIOUS PAGE